Pipeline

We are focused on the development of new products and supporting existing products, particularly through creating line extensions, focusing on innovative delivery systems and the use of advanced surface technology.

We have continued to advance our pipeline and expand its future potential by maximising existing technologies through R&D and also via strategicin-licensing and out-licensing activities. This approach will present us with significant pipeline development opportunities and new product asset as demonstrated by the addition of gynaecology as new therapeutic area following the out licensing deal with BMG Pharma and the licensing in of nano-silver technology. We also acquired proprietary organic zinc technology which may be combined with other technologies or used alone and a hydrogen peroxide delivery system which can be used as an antibacterialin wound healing treatments.

Marco Mastrodonato
Executive Vice-President

Mr Mastrodonato is responsible for the Business Development, Licensing and Products Development Division of the Group.

Highlights 2009

• Our current pipeline has 56 products and 12 stand-by products encompassing Dermatology, Oral Health and Gynaecology
• Deal with BMG Pharma to develop Sinclair’s existing gynaecological technology and create range of products
• Deal with major animal health company to evaluate the use of Delmopinol to treat or prevent periodontal disease in companion animals
• In-licensing of a range of skin anti-infection products based on patented silver nanotechnology
• Acquisition of proprietary organic zinc technology which may be combined with other technologies or used alone and a hydrogen peroxide delivery system which can be used as an antibacterial in wound healing treatments

Dermatology continues to be a focus area for the business

The use of advanced surface technology is a key area of focus

Sinclair has extended its patented technologies into the new therapeutic field of Gynaecology

 Sinclair received a licence fee from a major animal health company to enable it to evaluate the use of Delmopinol to treat or prevent periodontal disease in companion animals

R&D is focused on the development of new products and supporting existing products